Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.

ABSTRACT: Treatment-resistant schizophrenia (TRS) often results in severe disability and functional impairment. Currently, the diagnosis of TRS is largely exclusionary and emphasizes the improvement of symptoms that may not be detected early and treated according to TRS guideline. As the gold standard, clozapine is the most prescribed selection for TRS. Therefore, how to predict TRS in advance is critical for forming subsequent treatment strategy especially clozapine is used during the early stage of TRS. Although mounting studies have identified certain clinical factors and neuroimaging characteristics associated with treatment response in schizophrenia, the predictors for TRS remain to be explored. Biomarkers, particularly for peripheral biomarkers, show great potential in predicting TRS in view o

SUBMITTER: Jiao S 

PROVIDER: S-EPMC9597880 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature